alexa Identification And Validation Of HLA-A24 XBP1, CD138, And CS1 Peptides And Induction Of Antigensspecific CD8+ T Cell Immunity Using A Multipeptide Cocktail: Preclinical Basis For Vaccine Therapy In HLA-A24 Patients With Multiple Myeloma And Other Cancers
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Global Summit on Oncology & Cancer
May 25-27, 2017 Osaka, Japan

Jooeun Bae, Derin Keskin, Jun Zhou, Guanglan Zhang, Dharminder Chauhan, Teru Hideshima, Noopur Raje, Paul Richardson, Nikhil Munshi and Kenneth C Anderson
Dana-Farber Cancer Institute, USA
Harvard Medical School, USA
Boston University, USA
Massachusetts General Hospital, USA
VA Boston Healthcare System, USA
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-099
Abstract
XBP1 (X-box binding protein 1), CD138 (Syndecan-1) and CS1 (SLAMF7) are highly expressed antigens associated with tumor pathogenesis in cancers including multiple myeloma (MM) and various solid tumors. We have previously reported on the use of HLA-A2 peptides specific to these antigens to generate specific cytotoxic T cells (CTL). Vaccinations with these pooled peptides are currently in phase I/II clinical trials in patients with smoldering MM or triple negative breast cancer. The current studies extend this concept to the patients with HLA-A24, the second most dominant MHC-Class I in North America and the most common in Asia to broaden the patient population eligible for this cancer vaccine. Immunogenic HLA-A24 peptides derived from the antigens were evaluated. The identified XBP1 unspliced (UN)185-193 (I S P W I L A V L), XBP1 spliced (SP)223-231 (V Y P E G P S S L), CD138265-273 (I F A V C L V G F) and CS1240-248 (L F V L G L F L W) peptides were highly HLA-A24-specific and immunogenic, and induced ex vivo antigen-specific CTL with anti-MM activity in an HLA-A24 specific manner. Furthermore, a cocktail containing the four HLA-A24 peptides evoked MM-specific CTL with distinct phenotypic profiles (CD28, CD40L, 41BB, CD38, CD69) and antitumor activities, evidenced by perforin/CD107a/IFN-γ/IL-2/TNF-α production induced by HLA-A24+ MM cells. The multipeptidespecific CTL included antigen-specific memory CD8+ T cell subsets expressing T cell activation and immune checkpoints antigens (CTLA, PD1, LAG3, TIM3). Treatment of the multipeptide-CTL with specific inhibitors against mTOR, AKT, HDAC6 or specific immune checkpoints enhanced frequency/activation of antigen-specific central memory CTL and their anti-tumor activity. These results highlight the potential therapeutic application of an HLA-A24 multipeptide vaccine to induce MM-specific CTL with a broad spectrum of anti-tumor activity, which may extend to solid tumors (breast, colon, and pancreatic cancer) expressing these antigens.
Biography

Jooeun Bae has completed his PhD in Biomedical Science from Virginia Polytechnic Institute and State University, Blacksburg, Virginia. He holds a Master’s Degree in Major in Immunology and Microbiology from University of Maryland, Baltimore, Maryland followed by a Bachelor’s Degree from University of Maryland, Baltimore, Maryland. He attended the American Society for Hematology conference in San Diego, California USA.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords